Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06196658

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Early Phase I Study of Autologous T Cells Engineered to Express Anti-EX02 Chimeric Antigen Receptor (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Sponsor: Zeno Therapeutics Pte. Ltd

Conditions Advanced Biliary Cancer Pancreatic Cancer

Interventions anti-EX02 CAR T cells

Updated 3 times since 2024 Last updated: Dec 26, 2023 Started: Jan 1, 2024 Primary completion: Dec 30, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06196658, this EARLY_PHASE1 trial focuses on Advanced Biliary Cancer and Pancreatic Cancer and remains actively recruiting participants. Sponsored by Zeno Therapeutics Pte. Ltd, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zeno Therapeutics Pte. Ltd
Zhang Xiaofeng,MD

Data source: First People's Hospital of Hangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.